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ABSTRACT
Background Non-invasive ventilation (NIV) is an
effective form of treatment in patients with obesity
hypoventilation syndrome (OHS) who have concomitant
severe obstructive sleep apnoea (OSA). However, there is
a paucity of evidence on the efficacy of NIV in patients
with OHS without severe OSA. We performed a
multicentre randomised clinical trial to determine the
comparative efficacy of NIV versus lifestyle modification
(control group) using daytime arterial carbon dioxide
tension (PaCO2) as the main outcome measure.
Methods Between May 2009 and December 2014 we
sequentially screened patients with OHS without severe
OSA. Participants were randomised to NIV versus lifestyle
modification and were followed for 2 months. Arterial
blood gas parameters, clinical symptoms, health-related
quality of life assessments, polysomnography, spirometry,
6-min walk distance test, blood pressure measurements
and healthcare resource utilisation were evaluated.
Statistical analysis was performed using intention-to-treat
analysis.
Results A total of 365 patients were screened of whom
58 were excluded. Severe OSA was present in 221 and
the remaining 86 patients without severe OSA were
randomised. NIV led to a significantly larger improvement
in PaCO2 of −6 (95% CI −7.7 to −4.2) mm Hg versus
−2.8 (95% CI −4.3 to −1.3) mm Hg, (p<0.001) and
serum bicarbonate of −3.4 (95% CI −4.5 to −2.3)
versus −1 (95% CI −1.7 to −0.2 95% CI) mmol/L
(p<0.001). PaCO2 change adjusted for NIV compliance
did not further improve the inter-group statistical
significance. Sleepiness, some health-related quality of life
assessments and polysomnographic parameters improved
significantly more with NIV than with lifestyle
modification. Additionally, there was a tendency towards
lower healthcare resource utilisation in the NIV group.
Conclusions NIV is more effective than lifestyle
modification in improving daytime PaCO2, sleepiness and
polysomnographic parameters. Long-term prospective
studies are necessary to determine whether NIV reduces
healthcare resource utilisation, cardiovascular events and
mortality.
Trial registration number NCT01405976; results.
INTRODUCTION
Obesity hypoventilation syndrome (OHS) is charac-
terised by obesity and chronic hypercapnic
Key messages
What is the key question?
▸ Non-invasive ventilation (NIV) is an effective
form of treatment in patients with obesity
hypoventilation syndrome (OHS) who have
concomitant severe obstructive sleep apnoea
(OSA), but there is a paucity of evidence on the
efficacy of NIV in patients with OHS without
severe OSA.
What is the bottom line?
▸ NIV was more effective than lifestyle
modification in improving daytime PaCO2,
sleepiness and polysomnographic parameters.
Why read on?
▸ This randomised study demonstrates the
efficacy of NIV in this small subgroup of
patients with OHS without severe OSA where
central hypoventilation is the main mechanism
leading to daytime hypercapnia.
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respiratory failure in the absence of neuromuscular, metabolic,
lung or chest wall diseases.1 Although the majority of patients
with OHS have concomitant severe obstructive sleep apnoea
(OSA), nocturnal hypoventilation may be the only respiratory
sleep disorder present.2 In fact, in the largest clinical trial of
OHS, we recently reported that 73% had severe OSA.3
The prevalence of OHS in the general population is
unknown, but it has been estimated to be 0.3–0.4%.4 Given the
global obesity epidemic, the prevalence of OHS may be on the
rise. It is important for clinicians to promptly diagnose and
adequately treat OHS because, when left untreated, it is asso-
ciated with significantly worse cardiovascular morbidity, mortal-
ity and healthcare resource utilisation compared with eucapnic
OSA5 6 and eucapnic obese patients.5–13
The aetiology of daytime hypercapnia in OHS is complex and
not fully understood, but the progressive accumulation of CO2
caused by repetitive obstructive events (particularly with short
inter-event periods14 and non-apnoeic hypoventilation, mainly
rapid eye movement sleep hypoventilation) seems to be an
important contributor.15 Conceptually, continuous positive
airway pressure (CPAP) is not an effective treatment for patients
with OHS who are mostly hypoventilators without significant
OSA.16 Non-invasive ventilation (NIV), most commonly in the
form of bilevel positive airway pressure, can treat both apnoeic
and non-apnoeic nocturnal hypoventilation. In this phenotype of
patients with OHS who have a clear predominance of severe
OSA, both CPAP and NIV have been shown to decrease daytime
arterial carbon dioxide tension (PaCO2) in clinical series
7 10 16–20
and in three randomised controlled trials.3 21 22 However, in the
largest trial there were some respiratory functional advantages in
favour of NIV.3
The role of NIV in improving daytime hypercapnia in patients
with OHS who do not have concomitant severe OSA has only
been examined in three small case series of 22, 13 and 6
patients.23–25 Since most clinical series and clinical trials have
focused on OHS patients with severe OSA, there is a gap of
knowledge on how to most effectively treat patients with OHS
who do not have concomitant OSA.
To that end, we performed a multicentre randomised clinical
trial with two open parallel groups to compare the efficacy of
NIV versus lifestyle modification (control group) in patients
with OHS without severe OSA using PaCO2 at 2 months as the
primary outcome variable.
METHODS
Study design
This study was designed as a multicentre randomised clinical
trial with two open parallel groups. The present study is part of
the ‘Pickwick’ project.26 This project has two parallel rando-
mised clinical trials based on the presence or absence of severe
OSA (polysomnographic apnoea–hypopnoea index (AHI) ≥30)
with identical methodology (see online supplementary data).
Patients
Between May 2009 and March 2013 we sequentially screened
patients between 15 and 80 years of age who were referred for
pulmonary consultation due to suspected OHS or OSA at 16
tertiary hospitals in Spain with substantial experience with NIV
and CPAP therapy (see online supplementary data). In March
2013 recruitment and randomisation of OHS patients with
severe OSA was completed and from April 2013 to December
2014 we continued to sequentially include only patients with
OHS who did not have severe OSA. OHS was defined as
obesity with a body mass index (BMI) ≥30 kg/m2, stable
hypercapnic respiratory failure (daytime awake PaCO2
≥45 mm Hg, pH ≥7.35 and no clinical worsening during the
two previous months) and no significant chronic obstructive
pulmonary disease (COPD) (forced expiratory volume in 1 s
(FEV1) >70% of predicted when FEV1/forced vital capacity
(FVC) <70, neuromuscular, chest wall or metabolic disease.
Other inclusion criteria were an absence of narcolepsy or restless
leg syndrome and a correctly executed 30 min NIV treatment
test (see online supplementary data). The exclusion criteria were
as follows: (1) a psycho-physical inability to complete question-
naires; (2) severe chronic debilitating illness; (3) severe chronic
nasal obstruction; and (4) a lack of informed consent.
Ethics
The study was approved by the ethics committees of the 16 centres,
and written informed consent was obtained from all patients.
Randomisation
Conventional polysomnography (PSG) and analysis of arterial
blood gases (ABGs) were performed in enrolled participants.
Eligible patients were randomised by an electronic database
(simple randomisation) into the NIVor control group.
Control group: lifestyle modification
The lifestyle modification consisted of a 1000 calorie diet and
the maintenance of correct sleep hygiene and habits (avoiding
supine position during sleep; maintaining regular sleep habits
and exercise; not consuming sedatives, stimulants or alcohol;
not smoking tobacco; and avoiding heavy meals within 4 hours
before bedtime). Oxygen therapy was added if the daytime
arterial oxygen tension (PaO2) was <55 mm Hg
27 with the
necessary flow to maintain waking arterial oxygen saturation
(SaO2) between 88% and 92% or PaO2 ≥55 mm Hg for at least
17 hours/day. In patients requiring oxygen a new ABG analysis
was performed after 20 min of oxygen treatment. If PaCO2
increased to ≥5 mm Hg or if the pH reached <7.35, the
oxygen treatment was stopped.
NIV group
In addition to lifestyle modification and oxygen (if required),
patients were instructed to use NIV treatment during the entire
sleep period. The ventilator mode was set at bilevel pressure
with assured volume (ie, volume targeted pressure support).
While the patient was awake, the expiratory positive airway
pressure (EPAP) was initially set between 4 and 8 cm H2O and
the inspiratory positive airway pressure (IPAP) was set between
18 and 22 cm H2O (EPAP included). The pressures were
adjusted to obtain normal oxygen saturation, if possible, as mea-
sured by pulse oximetry and patient tolerance. The backup
respiratory rate was initially adjusted to 12–15 breaths/min
(close to the spontaneous respiratory rate, if possible) and the
target volume was set at between 5 and 6 mL/kg of actual
weight, allowing for an increase in the maximum pressure over
the previously minimum IPAP, if necessary. A check of mechan-
ical ventilation phases (trigger, pressurisation and ending) was
also performed to avoid asynchronies and to refine the setting.
After 30 min of continuous use with patient adaptation and an
adequate patient–ventilator interaction, an ABG analysis was
performed. The PaCO2 result was used to adjust the ventilator
parameters. The final adjustment was performed by means of
conventional PSG, with an increase in EPAP for obstructive
apnoeas and an increase in IPAP for hypopnoeas, flow limita-
tion, snoring or non-apnoeic hypoventilation, with the goal of
achieving normalisation of oxygen saturation or the maximal
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pressure tolerated was reached. No changes were made in the
assured volume during this nocturnal titration (see online sup-
plementary data for the ventilator and mask types employed).
Procedures and outcomes
Patients were evaluated on three occasions: at baseline, after the
first month and after 2 months. At baseline and after 2 months
we assessed the primary outcome (PaCO2) by means of ABG
analysis while breathing room air (see online supplementary
data). We also assessed the following secondary outcomes: other
ABG parameters; anthropometric data; clinical symptoms (clas-
sified into four levels of intensity); dyspnoea on the Medical
Research Council scale; sleepiness on the Epworth sleepiness
scale (ESS); health-related quality-of-life (HRQL) tests using the
Functional Outcomes of Sleep Questionnaire (FOSQ), the
Medical Outcome Survey Short Form 36 (SF 36) and the visual
analogue well-being scale (VAWS);28 29 blood pressure measure-
ments; PSG; spirometry; 6-min walk distance (6-MWD) test;
healthcare resource utilisation; dropouts and their causes; and
compliance using an hourly counter. In the first month we
encouraged treatment compliance, performed an ABG analysis
and made any necessary changes to the oxygen therapy or NIV
settings.
Dropouts were defined as patients who decided to leave the
study voluntarily or for one of the following medical reasons:
(1) pH <7.33 at the first month evaluation; (2) hospital admis-
sion requiring NIV treatment for more than 5 days, conven-
tional mechanical ventilation for more than 3 days or pH <7.33
while breathing room air at hospital discharge; or (3) death. We
considered adequate compliance with NIV treatment as daily
use for ≥4 hours.
PSG
We performed PSG at baseline for titration (only for the NIV
group) and after 2 months of treatment (with the home settings
of the NIV). Oxygen treatment was not applied during any
PSG. We used standard protocols to perform the PSG and
analyse the results (see online supplementary data). A valid PSG
recording required at least 3 hours of sleep time. In cases of an
invalid recording, the test was repeated one additional time.
Statistical analysis
The sample size was calculated based on a previous study in
which the mean PaCO2 in patients with OHS treated with NIV
was 45±5 mm Hg.23 We estimated the sample size required to
detect average differences of 2.5 mm Hg between groups using
a mean comparison of a sample versus a theoretical value
method. For a SD of 5 and power of 0.8, with a two-sided sig-
nificance level of 0.05, the estimated sample size was 34 patients
per group. When it was adjusted to a dropout rate of 20%, the
estimated sample size was 43 patients per group, or 86 in total.
Intention-to-treat analysis was performed. Missing values for
the primary and secondary outcomes (dropouts included) were
imputed following a multiple imputation method with iterative
multivariable regression because the missing data had character-
istics compatible with a missing at random pattern. Intra-group
changes in the continuous variables from baseline to 2 months
were assessed using paired t-tests. The observed effects in the
two arms of the study (inter-group differences) were compared
using unpaired t-tests. When the overall comparison was statis-
tically significant (p<0.05), comparisons of groups were per-
formed by analysis of covariance (ANCOVA), taking into
account the baseline values of the variable analysed such as age,
Figure 1 Flow chart of the study protocol. Of the 365 selected patients, 58 were excluded, 221 had severe OSA and 86 were randomised.
A dropout in the control group was due to hospital admission requiring NIV treatment for more than 5 days. OSA, obstructive sleep apnoea;
ITT, intention to treat; NIV, non-invasive ventilation.
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gender, BMI and AHI (henceforth ‘basic adjustment’).
An additional logistic regression was performed for the change
in the primary outcome with the basic adjustment, weight
change and NIV compliance (more or less than 4 hours of use
per day). Secondary categorical variables were compared
between baseline and 2 months using the χ2 test. Data manage-
ment, statistical analyses and the imputation were performed
using SPSS software (IBM SPSS Statistics V.22.0; IBM Corp,
Armonk, New York, USA).
RESULTS
Of the 365 patients who met the inclusion criteria, 58 were
excluded, 221 had severe OSA and 86 were randomised (figure 1).
Only one patient in each group was a dropout due to non-medical
causes.
Table 1 summarises the baseline demographic data. The
median age of the group was 68 years with a BMI of 40 kg/m2
and with a clear female predominance. The rates of comorbid-
ities were high, especially for hypertension, type 2 diabetes, dys-
lipidaemia and cardiovascular conditions. Patients assigned to
the NIV group had a lower frequency of dyslipidaemia and a
higher frequency of chronic heart failure than patients assigned
to the control group. Table 2 presents the baseline values and
the changes with treatment in the primary and secondary out-
comes. PaCO2 and serum bicarbonate levels improved with both
treatments. The improvements were significantly greater in the
NIV group, both in the unadjusted and adjusted inter-group
comparisons (table 2 and figure 2). Additionally, PaO2 improved
more with NIV without reaching inter-group statistical signifi-
cance. Although the 6-MWD test results improved more with
NIV treatment, it did not reach statistical significance in intra-
or inter-group comparisons.
Figure 2 shows the unadjusted and adjusted OR and 95% CIs
of the PaCO2 change between the NIV and control groups.
Adjustments for weight change and NIV compliance did not
substantially modify the inter-group statistical significances.
Table 3 presents the baseline values and the changes in the ESS
scores, HRQL results and weight with treatments. Although ESS
scores improved in both groups, the degree of improvement was
significantly larger with NIV. Additionally, significant improve-
ments were observed in the mental component of SF-36 and
VAWS questionnaires for the NIV group in the intra-group and
inter-group comparisons although, in the adjusted analysis, only
the mental component of SF-36 remained statistically
significant.
Figure 3 shows the clinical symptoms at baseline and after
2 months. NIV led to statistically significant improvements in
unrefreshing sleep and tiredness compared with controls.
Table 4 presents the baseline values and the changes in polysom-
nographic parameters. As expected, NIV significantly improved
Table 1 Anthropometric characteristics, alcohol and smoking
habits and comorbidities
NIV
(N=40)
Control
(N=46)
All
(N=86)
Gender, male, % 25 17 21
Age, years, median (IQR) 67 (12) 69 (15) 68 (14)
BMI, kg/m2, mean (SD) 40 (6.3) 40 (5.6) 40 (5.9)
Neck circumference, cm, median (IQR) 42 (7) 42 (5) 42 (5.8)
Waist circumference, cm, mean (SD) 123 (15) 119 (12) 121 (14)
Waist/hip ratio, mean (SD) 0.97 (0.1) 0.95 (0.08) 0.96 (0.09)
Active drinker, % 13 9 11
Alcohol, g, median (IQR) 30 (12) 23 (30) 30 (20)
Active smoker, % 7.5 15 12
Pack years, median (IQR) 35 (18) 40 (26) 38 (21)
COPD, %* 5.0 6.5 6.0
Hypertension, % 80 80 80
Drug number, median (IQR) 2 (1) 1 (1) 1 (1)
Diabetes, % 35 41 38
Dyslipidaemia, % 30 54 43
Ischaemic heart disease, % 11 8.7 9.5
Arrhythmia, % 16 7 11
Chronic heart failure, % 37 13 24
Stroke, % 8.1 8.9 8.5
Leg arteriopathy, % 14 15 15
Pulmonary hypertension, % 18 11 14
*Defined as FEV1 >70% of predicted when FEV1/FVC <70.
BMI, body mass index; NIV, non-invasive ventilation.
Table 2 Baseline measurements and changes with treatment related to the primary and secondary outcomes of pulmonary function and blood
pressure measures
Baseline, mean
(SD)/median (IQR)
Intra-group differences,
mean (95% CI)
p Value of inter-group
differences§
NIV Control NIV Control Unadjusted Adjusted
PaCO2, mm Hg 49 (4.0) 49 (3.5) −6 (−7.7 to −4.2)‡ −2.8 (−4.3 to −1.3)‡ 0.006 0.019
Serum bicarbonate, mmol/L 30 (4.1) 29 (3.8) −3.4 (−4.5 to −2.3)‡ −1 (−1.7 to −0.2)* 0.000 0.004
pH 7.400 (0.040) 7.400 (0.030) 0.005 (−0.005 to 0.157) 0.031 (−0.008 to 0.147) NS –
PaO2, mm Hg 64 (10) 67 (10) 4.6 (0.5 to 8.8)
* 1.4 (−2.6 to 5.5) NS –
FEV1, % 72 (16) 80 (20) 1.8 (−2.7 to 6.4) 1.9 (−1.2 to 5.1) NS –
FVC, % 75 (21) 82 (20) 4.7 (−4.2 to 14) 2.9 (−0.5 to 6.3) NS –
6-MWD, m 309 (105) 349 (105) 29 (−16 to 74) −7.2 (−25 to 11) NS –
Systolic BP, mm Hg 136 (18) 136 (15) −4.2 (−11 to 2.5) −4.3 (−10 to 1.7) NS –
Diastolic BP, mm Hg 80 (16) 80 (18) 0.5 (−5.3 to 6.2) −1.2 (−5.4 to 2.9) NS –
Median (IQR) values are shown in italic.
Bold type indicates statistical significance.
p Values of intra-group differences (2 months − baseline): *p<0.05; †p<0.01; ‡p<0.001.
§p Values of inter-group differences unadjusted or adjusted by basic adjustment (baseline values of the variable analysed and age, gender, BMI and AHI).
6-MWD, 6 min walk distance; AHI, apnoea–hypopnoea index; BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PaCO2, arterial carbon dioxide
tension; PaO2, arterial oxygen tension; NIV, non-invasive ventilation.
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AHI, arousal and desaturation indexes, mean oxygen saturation
and total sleep time (TST) below 90% oxygen saturation in
unadjusted and adjusted intergroup comparisons.
Table 5 shows the setting for NIV and oxygen, NIV compli-
ance and use of healthcare resource utilisation during the
follow-up period. Similar percentages of patients received sup-
plemental oxygen in both groups (NIV 25% and control 35%).
The mean backup respiratory rate was 15 breaths/min, the mean
IPAP was 18.2 cm H2O and the mean EPAP was 7.1 cm H2O.
The mean daily NIV use was 6±2.7 hours. NIV was more
effective than lifestyle changes in reducing emergency room
visits (NIV 0.05±0.22, control 0.23±0.52), but without reach-
ing statistical significance in the adjusted analysis.
Online supplementary figure E2 presents the PaCO2 at base-
line and at 1 and 2 months. Significant differences were
observed between baseline and 1-month values for the NIV
group, but there were no differences between 1-month and
2-month values. Additional details regarding the polysomno-
graphic titration, assured volume mode, dyspnoea and other
clinical symptoms, HRQL tests, transcutaneous PCO2, supple-
mental oxygen therapy and types of ventilators used are pro-
vided in the online supplementary data.
DISCUSSION
This study is the only randomised clinical trial to date comparing
two alternative treatment strategies in patients with OHS who do
not have concomitant severe OSA. The main results can be sum-
marised as follows: (1) PaCO2 and serum bicarbonate improved
significantly more in the NIV group than in the control group (ie,
lifestyle changes); (2) the improvement in PaCO2 with NIV treat-
ment was partially independent of NIV compliance, although
overall compliance with NIV was high in our cohort (mean
6 hours/night); and (3) AHI and nocturnal oxygenation
improved significantly with NIV treatment relative to the control
group. Our study is clinically relevant because the few rando-
mised clinical trials performed to date in patients with OHS have
focused on the phenotype that has concomitant severe OSA. Our
randomised clinical trial has provided clear evidence that NIV is
superior to lifestyle changes in this phenotype of patients with
OHS and severe OSA. Our present findings are in line with three
prior small clinical series of patients with OHS without severe
OSA treated with NIV.23–25 Moreover, the degree of improve-
ment in daytime PaCO2 observed in our study was similar to
prior studies that enrolled mostly patients with OHS and con-
comitant severe OSA,7 10 16–19 21 22 including our recently
reported largest clinical trial of OHS patients with severe OSA.3
Although there is no clear evidence as to what short-term
outcome variable is a reliable predictor of long-term out-
comes,7 13 18 we believe our choice of PaCO2 as the primary
outcome for this medium-term study is reasonable since PaCO2
is a marker of the severity of hypercapnic respiratory failure and
it has been related to mortality in OHS.12 18
Adequate compliance seems necessary to maximise the benefi-
cial effects of NIV therapy. However, in our study the PaCO2
change adjusted for compliance with NIV (>4 hours/day) did
not modify the inter-group statistical significance. This is in con-
trast to the findings in our recently published parallel rando-
mised clinical trial that included patients with OHS with severe
OSA.3 One possible explanation is that, in the present study, the
mean compliance was slightly higher leading to a ceiling effect
(6±2.7 vs 5.3±2.3 hours/day). Moreover, in our study patients
with OHS without severe OSA were phenotypically different
from patients with OHS with severe OSA.3 Those without
severe OSA were older, predominantly female, less obese, less
Figure 2 Inter-group changes in
arterial carbon dioxide tension (PaCO2)
(means and 95% of CIs) adjusted
according to basic adjustments
(baseline PaCO2, age, sex, body mass
index and apnoea–hypopnoea index),
weight change and non-invasive
ventilation (NIV) use (more or less than
4 hours/night).
Table 3 Baseline values and changes in the ESS score, health-related quality of life test results and weight
Baseline, mean (SD) Intra-group differences, mean (95% CI)
p Value of inter-group
differences
NIV Control NIV Control Unadjusted Adjusted
ESS 7.7 (5.5) 8.5 (4.2) −2.9 (−4.1 to −1.7)‡ −1.2 (−2.2 to −0.2)* 0.038 0.021
FOSQ 72 (22) 75 (19) 4.4 (−1.7 to 10.5) −2.7 (−8.1 to 3.1) NS –
SF 36-Physical 35 (10) 37 (8) 3.1 (−0.4 to 6.6) 0.9 (−1.3 to 3.2) NS –
SF 36-Mental 41 (12) 43 (11) 4.1 (0 to 8.3)† −0.9 (−3.7 to 1.8) 0.038 0.035
VAWS 45 (25) 63 (22) 18 (8.4 to 27)† 1.8 (−4.7 to 8.3) 0.006 –
Weight, kg 102 (19) 100 (17) 0.7 (−2.5 to 3.9) −1.6 (−3.1 to −0.2)* NS –
Bold type indicates statistical significance.
p Values of intra-group differences (2 months − baseline): *p<0.05; †p<0.01; ‡p<0.001.
p Values of inter-group differences unadjusted or adjusted by basic adjustment (baseline values of the variable analysed and age, gender, BMI and AHI).
AHI, apnoea–hypopnoea index; BMI, body mass index; ESS, Epworth sleepiness scale; FOSQ, Functional Outcomes of Sleep Questionnaire; NIV, non-invasive ventilation; SF 36, Medical
Outcome Survey Short Form 36; VAWS, visual analogue well-being scale.
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hypersomnolent, with a higher prevalence of hypertension and
cardiovascular morbidity, lower exercise tolerance and higher
rates of hospital admissions. Importantly, patients with OHS
without severe OSA did not have worse gas exchange during
wakefulness than patients with severe OSA.30 One might there-
fore surmise that, in addition to the PaCO2 level, there are
other important predictors of outcomes based on the phenotype
of OHS. Further investigations on OHS phenotypes,
‘dose-response’ of NIV treatment and long-term outcome are
necessary.
Several studies have reported an improvement in various mea-
sures of respiratory function in patients with OHS treated with
NIV,17 18 21 24 31 although these findings are not universal.10 11 17
In contrast to our recently published parallel randomised clinical
trial that included only patients with OHS with severe OSA,3 in
the present study we did not observe a significant improvement
in spirometry and 6-MWD tests in patients treated with NIV.3
The patients with OHS with severe OSA were more obese, and
it is plausible that NIV was more effective in reducing microat-
electasis leading to improvement in lung volume. In contrast to
patients with OHS with severe OSA,30 those without severe
OSA have a higher burden of cardiovascular morbidity which
may in part explain the lack of improvement in 6-MWD with
NIV therapy.
Although by design we excluded patients with severe OSA,
some degree of OSA was present in our patients (mean
AHI=14) and NIV significantly reduced the AHI and improved
other polysomnographic parameters of sleep-disordered breath-
ing such as arousal index, oxygen desaturation index and TST
<90% SaO2 compared with the control group. This finding is
similar observations in prior studies which predominantly
included patients with OHS with severe OSA,17 21 suggesting a
similar improvement in central hypoventilation in both OHS
phenotypes. In contrast to prior studies, we did not find any
improvement in the percentage of sleep stages, suggesting that
the improvement in sleep quality with NIV may be dependent
on the presence of severe OSA.
Observational studies have reported a reduction in long-term
healthcare resource utilisation in patients with OHS treated with
NIV.16 19 In our study we found a clear trend towards a reduc-
tion in healthcare resource utilisation with NIV treatment after
only 2 months of follow-up, although this degree of improve-
ment did not remain statistically significant in adjusted analysis.
A longer period of follow-up is necessary to better assess out-
comes such as healthcare resource utilisation.
Our study has several limitations. Given the multiple compari-
sons of secondary outcomes, those with p values close to the
statistical significance limit should be interpreted with caution
and taken as hypothesis-generating. With regard to the thresh-
old of OSA severity, we strategically opted to exclude patients
with severe OSA (AHI ≥30). Although we acknowledge that
most of our patients had some degree of mild to moderate OSA
(ie, AHI 5–29), we believe that CPAP is more effective in
improving hypercapnia in patients with OHS with severe OSA.
Moreover, from a pragmatic standpoint, enrolling patients with
OHS with minimal to no OSA would have been challenging
since the majority of patients with OHS do have some degree of
OSA. Although we recognise that our spirometric criteria may
have allowed the inclusion of some patients with mild COPD,
we believe that this degree of mild obstructive defect on spirom-
etry is less likely to be a significant contributor to the develop-
ment of chronic respiratory failure and hypercapnia, particularly
with an FEV1 >70% of predicted. Moreover, the low preva-
lence of COPD (6%) should have minimally impacted our
results.
Figure 3 Changes in the percentages of clinical symptoms in the two
groups. Non-invasive ventilation (NIV) achieved more important
improvement than the control group, with statistical intra-group
differences for unrefreshing sleep and tiredness.
Table 4 Baseline values and changes in polysomnographic parameters
Baseline, mean
(SD)/median (IQR) Intra-group differences, mean (95% CI)
p Value of inter-group
differences
NIV Control NIV Control Unadjusted Adjusted
TST, hours 5.3 (1.7) 5.4 (1.5) −0.15 (−1 to 0.6) 0.1 (−0.5 to 0.7) NS –
Sleep efficiency 77 (29) 79 (24) −5.4 (−15 to 4.6) 3.5 (−5.1 to 12) NS –
% Non-REM light sleep 67 (27) 63 (24) −6.2 (−15 to 2.3) −4 (−12 to 3.7) NS –
% Non-REM deep sleep 18 (17) 23 (18) 4.6 (−3.2 to 12) 1.6 (−6.4 to 9.6) NS –
% REM sleep 8.7 (8.9) 13 (15) 5.6 (−0.9 to 12) 3.3 (−3 to 9.6) NS –
Arousal index 25 (20) 22 (18) −10 (−14 to −6.2)‡ −0.3 (−2.9 to 2.3) 0.000 0.000
AHI 14 (8.9) 15 (7.8) −11 (−15 to −7.1)‡ 0.1 (−2.7 to 2.8) 0.000 0.000
DI 18 (27) 19 (16) −19 (−25 to −12)‡ −0.4 (−4.6:3.8) 0.000 0.000
Mean SaO2 88 (8) 87 (5) 6 (4.3 to 7.7)‡ 0.4 (−0.5 to 1.4) 0.000 0.000
%TST <90 82 (58) 69 (79) −36 (−46 to −25)‡ −5.7 (−15 to 2) 0.000 0.002
Median (IQR) values are shown in italic.
Bold type indicates statistical significance.
p Values of intra-group differences (2 months − baseline): ‡p<0.001.
p Values of inter-group differences unadjusted or adjusted by basic adjustment (baseline values of the variable analysed and age, gender, BMI and AHI).
AHI, apnoea–hypopnoea index; BMI, body mass index; DI, desaturation index; %TST <90, percentage of TST below 90% of oxygen saturation; NIV, non-invasive ventilation; REM, rapid
eye movement; SaO2, arterial oxygen saturation; TST, total sleep time.
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In summary, in the specific OHS phenotype without severe
OSA, NIV was more effective than lifestyle modification in
improving daytime PaCO2, sleepiness and polysomnographic
parameters of sleep-disordered breathing. Long-term rando-
mised controlled trials are necessary to demonstrate if NIV
decreases healthcare resource utilisation, cardiovascular events
and mortality and whether these outcomes are different
between phenotypes of OHS based on OSA severity.
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